BioPharma Credit PLC

BOPCFOTCFinancial Services● Active

$0.91

+$0.91(+82064.72%)

Market Cap$1.0B

P/E Ratio—

52W High$1.02

52W Low$0.8364

Avg Volume383K

Open$0.94

Beta0.18

Free Cash Flow Financials Revenue

BioPharma Credit PLC (BOPCF) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

BOPCF · free cash flow · updated Jun 8, 2026

Core FCF metrics

BOPCF · FCF · TTM · margin & CAGR

Free cash flow was $91.1M for FY2025 (fiscal year ending 2025-12-31), down 18.6% year-over-year The FCF margin was 65.0%. Five-year CAGR stands at +9.4%.

FY2025 Free Cash Flow$91.1M▼ -18.6% YoY

Trailing 12M (TTM)$203.0Mtrailing 4 quarters sum

FCF Margin65.0%$91.1M ÷ revenue

3-Year CAGR-20.9%FY2022 → FY2025

5-Year CAGR+9.4%FY2020 → FY2025

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

BOPCF · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$91.1M(0M)$91.1M▼ 18.6%65.0%

FY2024$111.9M(0M)$111.9M▼ 9.1%89.9%

FY2023$123.2M(0M)$123.2M▼ 33.2%90.8%

FY2022$184.3M(0M)$184.3M▲ +91.1%100.0%

FY2021$96.4M(0M)$96.4M▲ +66.1%109.6%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

BOPCF · P/FCF · FCF yield · FCF per share

BioPharma Credit PLC (BOPCF) trades at a FCF yield of 8.46% and a price-to-free-cash-flow ratio of 5.0x. FCF per share stands at $0.18, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

8.46%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$0.18

TTM FCF ÷ Shares Outstanding

Price / FCF

x5.0

Share Price ÷ FCF per Share

EV / FCF (TTM)

x11.7

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

BOPCF · cash flow statement · operating / investing / financing

For FY2025, BioPharma Credit PLC generated $91.1M in operating cash flow and spent 0M in capital expenditures, yielding $91.1M in free cash flow.

Operating Activities

+$91.1M

Cash from core business operations

2025-12-31

Investing Activities

+$77.5M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$161.6M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($91.1M) − |CapEx| (0M) = FCF ($91.1M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Financial Services)

BOPCF vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

BioPharma Credit PLCYOU

BOPCF

$91.1M-18.6%65.0%

Berkshire Hathaway Inc.

BRK-B

$25.04B+115.6%6.7%

25%

Berkshire Hathaway Inc.

Mastercard Incorporated

$16.91B+18.2%51.6%

17%

Financial Services · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

BioPharma Credit PLC (BOPCF) reported free cash flow of $91.1M for FY2025 (fiscal year ending 2025-12-31), down 18.6% year-over-year. The FCF margin was 65.0%.

Based on available data, BioPharma Credit PLC has maintained positive free cash flow for at least 9 fiscal year(s). FCF peaked at $184.3M in FY2022. The 5-year CAGR stands at +9.4%.

BioPharma Credit PLC's FCF yield is 8.46% and price-to-FCF ratio is 5.0x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

BOPCF free cash flow · 8 questions

BioPharma Credit PLC free cash flow was $91.1M for FY2025, down 18.6% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $203.0M.

BOPCF free cash flowBOPCF FCFBOPCF FCF 2025BOPCF free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · BioPharma Credit PLC · BioPharma Credit PLC SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026